Добавил:
kiopkiopkiop18@yandex.ru t.me/Prokururor I Вовсе не секретарь, но почту проверяю Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз: Предмет: Файл:
Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5851_Библиотеки_им_академика_М_И_Перельмана.pdf
Скачиваний:
0
Добавлен:
30.08.2026
Размер:
48 Мб
Скачать
Chapter 8
Acute Pulmonary Embolism
SoyoungKristiKim andLaurenA.Igneri

8.1 Introduction

Pulmonary embolism (PE) is a common yet serious clinical presentation of venous thromboembolism (VTE). VTE, including deep vein thrombosis (DVT) and PE, is the third most common acute cardiovascular syndrome globally, behind myocardial infarction and stroke [59]. Globally, the incidence of PE is reported to be between 39 (in Hong Kong) and 115 (in the United States) per 100,000 population [113].
Acute PE may present with varying degrees of critical illness, ranging from inci­dental ndings of asymptomatic PE to hemodynamic instability or cardiac arrest in high-risk patients with PE.Despite numerous advancements in the management of PE, the mortality rate for PE continues to be high. In high-risk patients, the 30-day mortality can be as high as 22% [73]. An analysis of epidemiologic databases reported the overall age-adjusted mortality per 100,000 populations as 2.84in 2006 compared to 2.81in 2019 [118].
Given the incidence and severity of illness associated with PE, pharmacist clini­cians should have an expanded understanding of the diagnostic process for the detection and management of PE.Pharmacists should be aware of the high rates of VTE that are associated with critical illness and develop during hospitalization. Hospital-acquired VTE accounts for more than half of all VTE reported in the United States [38]. The incidence of PE in critically ill patients in the intensive care unit (ICU) ranges from 1.4% to 2.9%, although the true incidence including unde­tected or asymptomatic PE may be higher [73].
S. K. Kim · L. A. Igneri (*) Clinical Pharmacy Specialist, Critical Care, Department of Pharmacy, Cooper University Health Care, Camden, NJ, USA e-mail: Igneri-Lauren@CooperHealth.edu
Switzerland AG 2025 Y. Alzaidi, M. A. Gebily (eds.), The Pharmacist’s Expanded Role in Critical Care Medicine, https://doi.org/10.1007/978-3-031-77335-8_8
171© The Author(s), under exclusive license to Springer Nature
172
S. K. Kim and L. A. Igneri
8.1.1 Risk Factors forVTE
Risk factors for the development of VTE are characterized as either acquired or inherited. Acquired risk factors include comorbidities such as hypertension, recent surgery, immobility, cancer, and obesity [101]. Patients may also have inherited risk factors for hypercoagulable states. The concept of antithrombin deciency leading to the loss of thrombin activity was proposed as early as 1905, forming the basis for there being genetic risk factors for VTE [22, 101]. Additional risk factors for inher­ited thrombophilia include factor V Leiden mutation, prothrombin gene mutation, and deciencies in protein S or C [22]. The identication of reversible or irrevers­ible acquired risk factors will play an important role in delineating provoked and unprovoked VTE, which determines the duration of anticoagulation therapy [59]. Table8.1 describes the weak, moderate, and strong predisposing factors for VTE.
8.1.2 Pathophysiology ofVTE
VTE often results from the presence of optimal conditions for thrombus formation as described by Virchow’s triad. This includes alterations in blood ow (e.g., venous stasis), endothelial damage, and hypercoagulable state as described above [101].
Table 8.1 Predisposing factors for VTE
Weak risk factors Moderate risk factors Strong risk factors
Diabetes mellitus Hypertension Immobility/bed rest Increasing age Laparoscopic surgery Obesity Pregnancy Varicose veins
Arthroscopic knee surgery Autoimmune diseases Blood transfusion Central venous lines Intravenous catheters and leads Chemotherapy Congestive heart failure or respiratory failure Erythropoiesis-stimulating agents Hormone replacement therapy (depends on formulation) In vitro fertilization Oral contraceptive therapy Post-partum period Infection (specically pneumonia, urinary tract infection, and HIV) Inammatory bowel disease Cancer (highest risk in metastatic disease) Paralytic stroke Supercial vein thrombosis Thrombophilia
Fracture of lower limb Recent hospitalization for heart failure or atrial brillation/utter Hip or knee replacement Major trauma Myocardial infarction Previous VTE Spinal cord injury
8 Acute Pulmonary Embolism
173
Thrombi typically form in the deep veins of the lower extremities, usually at sites of decreased ow such as valve cusps. Once microthrombi are formed due to venous stasis or endothelial injury, blood ow is further impeded. This progresses to further vascular injury and clot formation, perpetually activating the coagulation cascade [71]. Thrombus that originates from a venous bed may resolve completely or par­tially via recanalization, organization, and/or lysis or continue to expand and embo­lize to the pulmonary circulation [71, 101].
8.1.3 PE Denitions andClassications
8.1.3.1 Pathogenesis ofPE
PE often results from a thrombus originating in the lower extremity proximal veins (e.g., iliac, femoral, or popliteal) that travels to the pulmonary vasculature. Emboli follow normal venous circulation, from the vena cava to the right atrium and ven­tricle, and then ultimately to the pulmonary artery and its branches. The presence of specic patient factors such as the use of pacemakers, implantable debrillators, and indwelling central venous catheters may increase the risk of an upper extremity DVT that embolizes the pulmonary arteries [71, 101]. In the Registro Informatizado de la Enfermedad Tromboembolica (RIETE) registry of patients with documented VTE, the rates of PE at 90days were similar regardless of the origin of the thrombus in the upper or lower extremity [74]. In rare instances, thrombus may originate directly from the pulmonary vasculature without evidence of DVT.Factors such as endothelial cell dysfunction, hypoxia, and inammation may lead to this phenom­enon of in situ PE. This can be observed in patients with trauma (such as chest contusions), sickle cell disease, pulmonary tuberculosis, and other systemic dis­eases. Seldom, pulmonary embolism develops from non-thrombotic causes, such as air, fat, or tumor emboli that obstruct the pulmonary artery or its branches [71, 110]. The pathophysiology, diagnosis, and management of non-thrombotic PE are beyond the scope of this chapter. There are multiple ways to characterize PE, including its anatomic location, chronicity, and risk stratication, which are described in Table8.2.
8.1.3.2 Anatomic Location
The anatomic location of thrombi further straties PE.A large clot that lodges at the bifurcation of the main pulmonary artery leads to a saddle PE.A saddle embolus obstructs the blood ow to both the right and left pulmonary arteries. Smaller emboli that travel beyond the pulmonary artery bifurcation can lodge distally in the lobar, segmental, or subsegmental branches. Occlusions of a distal pulmonary artery (segmental and subsegmental) can lead to pulmonary infarction, potentially causing ischemia, hemorrhage, and tissue necrosis. Due to the location of the emboli, saddle
174
Table 8.2 Characterization of PE
Characteristics Categories Denition
Anatomic Saddle Emboli at the bifurcation of the main pulmonary artery
Lobar Emboli at the lobar branches Segmental Emboli at the segmental branches Subsegmental Emboli at the subsegmental branches
Chronicity Acute Immediate or recent symptoms
Subacute Symptoms over weeks to months Chronic Symptoms lasting months to years
Risk Low Refer to Table8.5
Intermediate-
ow
l Intermediate-
high High
S. K. Kim and L. A. Igneri
PE was historically assumed to be associated with more hemodynamic compromise compared to PE caused by distal thrombi. However, no difference in mortality was observed between a saddle and non-saddle PE in a recent retrospective review, which highlights the importance of cautiously monitoring all patients for signs of decompensation regardless of the anatomic location of the emboli [41].
8.1.3.3 Chronicity
Patients can present with acute, subacute, or chronic PE.The duration of patient symptoms such as cough or shortness of breath differentiates patients into one of the three categories. Patients with acute PE present with immediate or recent symp­toms, whereas those with subacute PE may report symptoms that are presented insidiously over weeks to months [26, 96]. In contrast, patients with chronic PE often present with symptoms lasting months to years. Although most patients recover fully after the resolution of acute embolism, approximately 30–50% of patients have perfusion defects and residual pulmonary obstruction at 6months from diagnosis despite anticoagulation [115].
Patients with chronic PE may develop pulmonary hypertension from unresolved pulmonary occlusions in the pulmonary arteries, subsequent brosis, and remodel­ing of the pulmonary vessels leading to elevated pulmonary vascular resistance (PVR) [76]. This unique pathophysiology is known as chronic thromboembolic pul­monary hypertension (CTEPH), also designated as Group 4 pulmonary hyperten­sion by the World Health Organization. Although the incidence of CTEPH is not clearly dened, it is identied in 0.5–9% of patients following acute PE [115].
Treatment for CTEPH can be highly variable and requires multidisciplinary team evaluation. All eligible patients without contraindications should receive indenite anticoagulation. For patients that are operable candidates, pulmonary
8 Acute Pulmonary Embolism
175
thromboendarterectomy (PTE) may be a curative therapy. In recent years, balloon pulmonary angioplasty emerged as an established treatment option for patients who are not surgical candidates [115]. Patients may also receive pulmonary hypertension­specic therapies, such as pulmonary vasodilators or remodeling agents that lower the pulmonary vascular resistance (PVR) and pulmonary artery pressure (PAP) [52]. Riociguat, a soluble guanylate cyclase stimulator approved for use in inoper­able CTEPH or persistent CTEPH following PTE, was shown to improve 6-minute walking distance and PVR in the CHEST-1 study [33].
8.1.3.4 Risk Stratication
Patients are further categorized according to the risk of mortality and poor out­comes. Previously, PE was often stratied as massive, submassive, or nonmassive/ low risk depending on the hemodynamic stability, although denitions of hemody­namic stability have varied. The 2011 scientic statement from the American Heart Association dened massive PE as an acute PE with sustained hypotension, pulsel­essness, or persistent profound bradycardia. The term submassive PE was utilized to describe acute PE without systemic hypotension but with either RV dysfunction or myocardial necrosis, and low-risk PE was dened as acute PE in the absence of the clinical markers of adverse prognosis that dene massive or submassive PE [42]. These denitions are important to acknowledge since historical primary literature frequently utilized such terminology to stratify patients. Newer guidelines, includ­ing the one published by the European Society of Cardiology in 2020, transitioned to categorizing PE as high, intermediate-high, intermediate-low, and low risk [59]. The risk stratication ultimately guides diagnostic and treatment strategies in PE, which are discussed in forthcoming sections.

8.1.4 Clinical Presentation

8.1.4.1 Symptoms
Patients with acute PE may present with a multitude of nonspecic symptoms or with abnormal cardiopulmonary exams that mimic numerous other disease states including:
• Pleuritic chest pain
• Dyspnea
• Apprehension
• Angina chest pain
• Cough
• Diaphoresis
• Hemoptysis
176
S. K. Kim and L. A. Igneri
• Lightheadedness
• Leg or thigh pain/swelling
• Orthopnea
• Palpitations
• Syncope
• Wheezing
PE should be included in the differential diagnosis when unexplained or rapid­onset dyspnea, pleuritic chest pain, or hemoptysis is present. Particularly, in patients with preexisting heart or pulmonary disease, dyspnea may be the most prominent symptom. However, dyspnea was experienced by 73% of patients with PE despite no preexisting cardiopulmonary conditions in the PIOPED II registry, at rest or with exertion [98]. Pleuritic chest pain is typically the result of pleural irritation from distal emboli that causes pulmonary infarction, whereas chest pain that mimics acute coronary syndrome or aortic dissection may be caused by RV ischemia from extensive central PE [101]. Symptoms suggestive of DVT (e.g., erythema, warmth, pain, swelling, tenderness) may also warrant further evaluation for PE, as PE often arises from a thrombus in the lower extremity. In the same registry, 44% of patients with PE experienced concomitant leg or thigh symptoms [98].
Patients with high-risk PE may present with hemodynamic instability such as systemic hypotension, RV dysfunction, presyncope or syncope, and even cardiopul­monary arrest [59, 101]. These features are more pronounced in patients with a greater magnitude of embolism or in patients with preexisting cardiac comorbidities [59, 101]. Finally, some patients with PE may be asymptomatic on presentation, making workup challenging.
8.1.4.2 Physician Examination
Similarly to presenting symptoms, patients with PE may have variable physical exam ndings that mimic other disease states [101]:
Anxiety
• Chest-w
Fever
all tenderness
• Heart failure
Le
g or thigh swelling/tenderness
Neck v
ein distention
Shock
• Tachycardia
• Tachypnea
• Wheezing
Patients with PE frequently present with tachypnea and tachycardia, which may confound the diagnoses by mimicking potential infectious etiologies. Particularly when patients have concomitant fever or shock, the treatment team may focus the
8 Acute Pulmonary Embolism
177
management on antimicrobials for pneumonia or sepsis. The pharmacist’s involve­ment in the appropriate evaluation of these nonspecic clinical ndings can mini­mize unnecessary antimicrobial usage in patients with PE.
The severity of a patient’s physical examination may depend on the patient’s baseline cardiopulmonary reserve. Patients with a concomitant cardiac or pulmo­nary disease may not possess the adequate compensatory mechanism to overcome the clot burden in the pulmonary vasculature, leading to worsening hemodynamics [71, 101].
8.1.4.3 Cardiopulmonary Compromise
Pulmonary embolism may impair not only gas exchange, but also systemic circula­tion [59]. Whereas small emboli block the peripheral arteries and precipitate pulmo­nary infarction, large saddle embolus can obstruct the main pulmonary artery and have a grave impact on the cardiovascular system.
Hypoxemia from PE develops due to various mechanisms. The obstruction of the pulmonary vascular bed causes decreased capillary blood ow, leading to intrapul­monary shunting, increased alveolar dead space, ventilation-perfusion (V/Q) ratio mismatch, and decreased mixed venous oxygen saturation. V/Q mismatch occurs from zones of reduced ow in the obstructed vessels and zones of overow in non­obstructed vessels. Atelectasis, alveolar hemorrhage, or bronchoconstriction can also lead to worsening shunt physiology [101, 110]. Low CO from RV failure also contributes to the reduced mixed venous oxygen saturation.
PE may cause hemodynamic alterations to varying degrees. When less than 20% of the pulmonary vascular bed is occluded by thromboemboli, patients without pre­existing cardiopulmonary disease are able to elicit compensatory mechanisms to support near-normal hemodynamics [101]. PE-induced hypoxemia causes neuro­hormonal activation of thromboxane A2 and serotonin, leading to initial vasocon­striction and increased PVR. When 30–40% of the pulmonary bed is occluded, PAP increases, and the RV adapts by increasing the stroke volume to maintain cardiac output (CO). This compensatory mechanism temporarily improves ow through the obstructed pulmonary vascular bed and stabilizes systemic blood pressure. However, the effect is short-lived as the thin-walled RV cannot generate a consistent mean PAP >40mmHg. When pulmonary obstruction exceeds 50–60%, or when the com­pensatory mechanism is overwhelmed, drastic cardiovascular collapse can ensue. The increase in PVR leads to RV dilation, increased RV wall tension, and attening of the interventricular septum, which alter the contractility of the myocardium. Ultimately, abrupt RV failure and desynchronization of the ventricles result in LV lling impedance, reduction in CO, and hemodynamic instability [101]. RV failure is attributed as the main cause of death in severe PE [59]. Patients with preexisting cardiopulmonary disease may have an exaggerated response to smaller degrees of pulmonary vascular occlusion, leading to severe pulmonary hypertension dispro­portionate to the degree of obstruction from acute PE [101].
178
8.2 Diagnosis andRisk Assessment
S. K. Kim and L. A. Igneri
8.2.1
8.2.1.1 Clinical Pretest/Scores
Clinical pretest probability scoring is a cornerstone of diagnostic algorithms for PE as it guides selection of tests based on an assessment of the patient’s signs and symptoms, risk factors for PE, presence of DVT, and whether PE is the most likely diagnosis, thereby allocating resources to patients most likely to derive benet from testing (e.g., conrm or refute diagnosis of PE) [59]. Comparatively, pretest assess­ment using clinical gestalt lacks standardization, and preference should be to use clinical prediction rules for workup of PE.
ability scores as they inform the need for further diagnostic testing and provide an opportunity to strategize potential initial anticoagulation selection while conrma­tory tests are pending. The most widely used clinical pretest scores for PE include the Wells scores, Geneva Clinical Prediction, and PE Rule-Out Criteria and are compared in Table8.3.
estimate the clinical pretest probability of PE as either low, moderate, or high and is one of the most widely utilized and validated pretest probability scoring tools for PE [111, 112]. In the study validating the score in the emergency department (ED), PE was excluded in patients with a low pretest score and negative D-dimer and no imaging was performed. Comparatively, 40.6% of patients in the high-probability group and 16.2% in the moderate-probability group with positive D-dimer were diagnosed with PE.Only 1.3% of patients in the low-probability group re-presented back to the ED and were ultimately diagnosed with PE [112]. Subsequently, the score was simplied to “PE unlikely” or “PE likely” and validated in the Christopher Study [106]. In patients classied as unlikely, PE was excluded if the D-dimer was normal, and most patients did not receive anticoagulation. Only 0.5% were found to have subsequent PE at 3-month follow-up [106]. This score was also validated in conjunction with the use of an age-adjusted D-dimer cutoff in ADJUST-PE, a mul­ticenter, multinational prospective management outcome study of outpatients with suspected PE [88]. Similarly, the Geneva clinical prediction rule, which originally incorporated seven variables, was revised to eight variables, simplied, and then validated in the ADJUST-PE [88].
the Pulmonary Embolism Rule-Out Criteria (PERC) were developed to identify those with a low risk for PE who do not require further workup [59]. When there is low clinical suspicion for PE and the patient meets all eight criteria, a diagnosis of PE should not be pursued. Penaloza and colleagues found that when all PERC cri­teria were met in patients with a low gestalt assessment, PE prevalence was zero [80]. Subsequently, a prospective, observational study demonstrated that PERC had
Diagnostic
The pharmacist clinician should be familiar with the most common pretest prob-
The Wells score incorporates seven criteria with the evaluation of D-dimer to
To prevent unnecessary testing for PE in the emergency department (ED) setting,
Workup
8
cute Pulmonary Embolism
A
179
Table 8.3
88, 111, 112]
Wells Score Geneva Clinical Prediction
Variables Points Variables
Clinically suspected DVT
Alternative diagnosis is less likely than PE
Heart rate >100 beats/min
Immobilization or surgery in previous 4weeks
History of VTE 1.5 Active cancer 2 1 No hemoptysis Hemoptysis 1 Unilateral
Malignancy or treatment for it in previous 6months
Interpretation Clinical
Probability Points
Three-level prediction
High
Two-level prediction
High
Comparison of
probability
Moderate
probability
Low probability ≤4
probability
Low probability ≤4
Wells scores, Geneva Clinical Prediction, and PE Rule-Out Criteria [59,
PE Rule-out Criteria Rule
Clinical Decision Rule Points
VariablesOriginal Simplied
3 Previous PE or
3 Heart rate Pulse <100 beats/
1.5 Surgery or fracture
1.5 Hemoptysis 2 1 No unilateral leg
1 Pain on lower-limb
6.5 Low 0–3 0–1
4.5–
6.0
>4 PE unlikely 0–5 0–2
DVT
75–94 beats/minute 3 1 95 beats/minute 5 2
within past month
lower-limb pain
deep venous palpation and unilateral edema
Age>65 1 1 No oral hormone use
Clinical Probability Points Clinical Probability
Three-level score If all variables met
Intermediate 4–10 2–4
High ≥11 ≥5
Two-level score
PE likely ≥6 ≥3
3 1 Age <50years
minute
2 1 Pulse oximetry
>94%
swelling
3 1 No surgery or trauma
within 4weeks
4 1 No prior DVT or PE
combined with low clinical suspicion for PE, diagnosis of PE should not be pursued
180
S. K. Kim and L. A. Igneri
a low rate of false-negatives for excluding PE in low-risk patients, and a crossover cluster-randomized trial found that PERC was noninferior to the gestalt method [30, 81].
8.2.1.2 D-Dimer-Level Interpretations
D-dimer levels become elevated in acute thrombosis due to activation of the coagu­lation cascade and plasmin-mediated enzymatic degradation of cross-linked brin clot [50]. While normal D-dimer levels (generally <500ng/mL) have a high nega­tive predictive value to rule out PE, high D-dimer levels have a low positive predic­tive value and are not useful as a conrmatory test [59].
Several D-dimer assays are available, but the quantitative enzyme-linked immu­nosorbent assay (ELISA) has >95% sensitivity to exclude PE in patients with low or intermediate pretest probability. Many studies have shown that a negative D-dimer in combination with low or intermediate clinical pretest probability scores excludes PE without the need for further testing [30, 80, 81, 88, 112]. When anticoagulation is withheld due to the negative result, the risk of developing PE at 3months is <1% [14].
It is important for the pharmacist clinician to be aware of disease states that may cause false elevations in D-dimer to aid with the interpretation of result, especially when used in conjunction with pretest probability scoring. Other physiologic states or conditions that may result in elevated D-dimer in the absence of VTE include pregnancy, malignancy, cigarette smoking, trauma, infection, or sepsis. Additionally, patients who are older, immobilized, and with autoimmune disorders or have had recent surgery may have an elevated D-dimer without having VTE [12].
Recently, alternative D-dimer thresholds have been evaluated to optimize the proportion of patients who ultimately receive conrmatory imaging studies and are found to have PE.
Several studies have shown that D-dimer levels increase with age, limiting the util­ity of D-dimer thresholds <500ng/mL to rule out PE in older individuals, especially those greater than age 80. The age-adjusted D-dimer threshold of patient age multi­plied by 10ng/mL in individuals over age 50 has been prospectively evaluated. In the ADJUST-PE study, clinical pretest probability scoring was evaluated with either the simplied Geneva score or the two-level Wells score. Patients with low/intermediate or unlikely probability had D-dimer testing performed, with a negative test dened as <500ng/mL (patient age <50) or less than the age-adjusted level (patient age 50). In patients with D-dimer between 500 and their age-adjusted threshold, the rate of VTE at 3months was 0.3%. Among patients >75years, the use of age-adjusted D-dimer increased the proportion of patients in whom PE could be excluded from 6.4% with the standard threshold to 29.7% without any additional false-negative ndings [88].
Due to the risks associated with radiation and contrast media, clinical probability­adapted D-dimer thresholds have been evaluated to reduce exposure to conrmatory testing in patients unlikely to have PE.The PEGeD study used the Wells clinical pretest probability scoring with D-dimer <1000 ng/mL in low-probability and <500ng/mL in moderate-probability patients to exclude PE and further workup in